Nurix Therapeutics, Inc. NRIX Business Segments — R&D
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Nurix Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nurix Therapeutics, Inc.'s business segments — r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nurix Therapeutics, Inc.'s business segments — R&D?
- Nurix Therapeutics, Inc. (NRIX) reported business segments — R&D of $84.14M in Q4 2025.
- How has Nurix Therapeutics, Inc.'s business segments — R&D changed year-over-year?
- Nurix Therapeutics, Inc.'s business segments — R&D increased by 20.8% year-over-year, from $69.66M to $84.14M.
- What does business segments — R&D mean?
- This metric represents the total operating expenses dedicated to the discovery and clinical development of novel therapeutic candidates within the company's primary business segment. It encompasses costs associated with laboratory research, preclinical studies, and clinical trial execution for the company's protein modulation pipeline. Monitoring this expenditure provides insight into the company's commitment to advancing its drug development portfolio and its long-term investment in future revenue-generating assets.